Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet
Aug 15, 2020 Volume 396 Number 10249 p447-512
https://www.thelancet.com/journals/lancet/issue/current

 

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
Feng-Cai Zhu, et aL